Cargando…
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876590/ https://www.ncbi.nlm.nih.gov/pubmed/26585523 http://dx.doi.org/10.2174/1570159X14666151120123025 |
_version_ | 1782433261395378176 |
---|---|
author | Dong, Jie Cui, Yanhua Li, Song Le, Weidong |
author_facet | Dong, Jie Cui, Yanhua Li, Song Le, Weidong |
author_sort | Dong, Jie |
collection | PubMed |
description | Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD. |
format | Online Article Text |
id | pubmed-4876590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-48765902016-11-01 Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease Dong, Jie Cui, Yanhua Li, Song Le, Weidong Curr Neuropharmacol Article Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD. Bentham Science Publishers 2016-05 2016-05 /pmc/articles/PMC4876590/ /pubmed/26585523 http://dx.doi.org/10.2174/1570159X14666151120123025 Text en ©2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Dong, Jie Cui, Yanhua Li, Song Le, Weidong Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title_full | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title_fullStr | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title_full_unstemmed | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title_short | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
title_sort | current pharmaceutical treatments and alternative therapies of parkinson's disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876590/ https://www.ncbi.nlm.nih.gov/pubmed/26585523 http://dx.doi.org/10.2174/1570159X14666151120123025 |
work_keys_str_mv | AT dongjie currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease AT cuiyanhua currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease AT lisong currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease AT leweidong currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease |